Exelixis Inc
EXEL
Company Profile
Business description
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Contact
1851 Harbor Bay Parkway
AlamedaCA94502
USAT: +1 650 837-7000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
1,310
Exelixis Inc News & Analysis
stocks
9 mid-cap stocks for your US pick list
Clothing retailer Gap, brewer Molson Coors and Exelixis, which develops kidney and liver cancer treatments, are among recent additions to Morningstar's list of mid-sized US companies trading at attractive prices.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,704.10 | 44.50 | 0.51% |
| CAC 40 | 7,143.03 | 51.48 | -0.72% |
| DAX 40 | 19,261.75 | 34.23 | -0.18% |
| Dow JONES (US) | 44,722.06 | 138.25 | -0.31% |
| FTSE 100 | 8,274.75 | 16.14 | 0.20% |
| HKSE | 19,523.57 | 79.56 | -0.41% |
| NASDAQ | 19,060.48 | 115.10 | -0.60% |
| Nikkei 225 | 38,059.50 | 75.47 | -0.20% |
| NZX 50 Index | 13,086.44 | 126.48 | -0.96% |
| S&P 500 | 5,998.74 | 22.89 | -0.38% |
| S&P/ASX 200 | 8,448.70 | 42.00 | 0.50% |
| SSE Composite Index | 3,311.43 | 1.65 | 0.05% |